1 Endocrine and anti-fertility studies were carried out on a fluorinated bibenzyl, bifluranol, in rats and mice. 2 A potent anti-prostatic activity of bifluranol was shown to be comparable to diethylstilboestrol (DES). In contrast, its oestrogenic potency by the oral route was about eight times less than that of DES. 3 In comparative short and long-term anti-androgenic and fertility studies in rats and in studies on sexual potency and reproductive performance in male mice, bifluranol given orally was shown to produce fully reversible suppression of accessory sexual structures without impairment of spermatogenesis and fertility. In contrast, DES administered in the same dose reduced spermatogenesis as well as accessory sexual glands. 4 Bifluranol lowered serum luteinising hormone (LH) levels without affecting follicle stimulating hormone (FSH). Under similar conditions DES reduces both LH and FSH levels. Since bifluranol does not antagonize androgen-induced stimulation of the prostate in castrated rats, its anti-prostatic effect is interpreted as a negative, hormonostatic feedback activity, mediated through a selective inhibition of LH secretion.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2044395 | PMC |
http://dx.doi.org/10.1111/j.1476-5381.1980.tb10903.x | DOI Listing |
Chem Biodivers
November 2024
Key Laboratory of Tropical Marine Bioresources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Pipefish is traditionally used as a male tonic in China. Recent studies have shown that Syngnathus schlegeli extracts effectively combat benign prostatic hyperplasia (BPH). However, the specific active compounds involved and their mechanisms of action are not fully understood.
View Article and Find Full Text PDFChin Herb Med
July 2024
College of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
The genus is a multi-origin animal species with high medicinal and healthcare values. About 57 species of spread worldwide, of which about 14 species can be used as medicine, showing anti-oxidation, anti-inflammation, anti-depressant, anti-hypertension, anti-prostatic hyperplasia, antivirus, anti-apoptotic, antifatigue, and so on. And those pharmacological effects are mainly related to their active ingredients, including amino acids, abundant proteins (peptides and oligopeptides), fatty acids, nucleosides, steroids, and other small molecular compounds.
View Article and Find Full Text PDFMolecules
January 2023
Molecular Biotechnology and Health Sciences Department, University of Torino, Via Quarello, 15, 10135 Torino, Italy.
Proteolysis-Targeting Chimeras (PROTACs) have recently emerged as a promising technology in the drug discovery landscape. Large interest in the degradation of the androgen receptor (AR) as a new anti-prostatic cancer strategy has resulted in several papers focusing on PROTACs against AR. This study explores the potential of a few in silico tools to extract drug design information from AR degradation data in the format often reported in the literature.
View Article and Find Full Text PDFLife (Basel)
May 2022
Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
Aeroplysinin-1 is a brominated isoxazoline alkaloid that has exhibited a potent antitumor cell effect in previous reports. We evaluated the cytotoxicity of aeroplysinin-1 against leukemia and prostate cancer cells in vitro. This marine alkaloid inhibited the cell proliferation of leukemia Molt-4, K562 cells, and prostate cancer cells Du145 and PC-3 with IC values of 0.
View Article and Find Full Text PDFJ Immunother Cancer
May 2021
Department Hematology/Oncology, School of Medicine, University of California San Francisco, San Francisco, California, USA
Background: Sipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after sipuleucel-T could modify immune and/or clinical responses to this treatment.
Methods: A total of 50 patients with mCRPC were enrolled into a clinical trial (NCT01804465, ClinicalTrials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!